Anosheh Afghahi

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes

Joshua J. Gruber, Anosheh Afghahi, Kirsten M. Timms et al. · Nature Cancer · 2022 · 124 citations · Full text

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Anosheh Afghahi, Natasha Purington, Summer S. Han et al. · Clinical Cancer Research · 2018 · 99 citations · Full text

Tumor <i>BRCA1</i> Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

Anosheh Afghahi, Kirsten M. Timms, Shaveta Vinayak et al. · Clinical Cancer Research · 2017 · 70 citations · Full text

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

Shira Dinner, Wesley Witteles, Anosheh Afghahi et al. · Haematologica · 2013 · 60 citations · Full text

Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in <i>BRCA1</i> and <i>BRCA2</i> wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.

Joshua J. Gruber, Anosheh Afghahi, Alyssa Hatton et al. · Journal of Clinical Oncology · 2019 · 48 citations

Breast Oncology, Pathology, Talazoparib Monotherapy +18